The field of oncology has witnessed numerous advancements over the years, but the introduction of molecular glue degraders marks a significant leap forward. These innovative small molecules are poised to transform cancer treatment by targeting previously "undruggable" proteins, offering
The U.S. Department of Defense has awarded a substantial grant of $11.9 million to the Oregon State University (OSU) College of Pharmacy, with the aim of developing advanced drug delivery technologies specifically designed to protect military personnel from various health threats encountered in
Imagine a world where getting vaccinated no longer means facing a needle and syringe, but instead, involves a simple patch applied to the skin. This prospect is rapidly becoming a reality thanks to the innovative work of the University of Queensland (UQ) and Brisbane-based biotech company Vaxxas.
Aneuploidy, the presence of an abnormal number of chromosomes within a cell, is widely recognized as a defining hallmark of cancer. This association has guided cancer diagnostics and research for years, embedding in the scientific community's understanding of how cancers develop and progress.
Glioblastoma multiforme, an aggressive form of brain cancer, has long been a formidable challenge in the medical field. With patient survival rates stagnating around 15 to 18 months, the need for innovative treatment approaches is critical. NeOnc Technologies, under the leadership of Dr. Thomas
The pharmaceutical industry is on the brink of significant transformation, driven by advancements in oncology, artificial intelligence (AI), and evolving policy landscapes. As we look towards 2025 and beyond, these changes promise to revolutionize drug development, clinical trials, and patient
